Building the future of first-in-class THCA therapeutics
Built to answer one underexplored scientific question.
Can purified tetrahydrocannabinolic acid be translated into a reproducible pharmaceutical candidate and evaluated rigorously in chronic inflammatory disease?
THCA Therapeutics is a Munich-based, biotechnology business created to investigate that question through disciplined formulation development, analytical control, nonclinical research, regulatory planning and future clinical translation.
Purified THCA focus
A dedicated development strategy centered on THCA itself rather than consumer cannabis products or THC generation.
Rheumatoid arthritis first
One lead indication creates a focused path for candidate development, evidence generation and translational decision-making.
Evidence before claims
Published preclinical findings provide a rationale for research. Product-specific human safety and efficacy must still be established.
Platform with discipline
THCA PURE™ is intended to support multiple delivery programs, but expansion occurs only when evidence and resources justify it.
From scientific curiosity to a structured development thesis.
The origin of THCA Therapeutics is founder-led. Personal observation and long-term curiosity helped define the initial question; published research and future controlled studies must determine the answer.
Interest in THCA and non-heated cannabinoid biology
Founder-led exploration begins around the distinction between THCA and THC and the limited clinical understanding of the acidic molecule.
Published findings are mapped and critically assessed
Laboratory and animal evidence is reviewed across inflammatory, neurological, metabolic and supportive-care research areas.
Rheumatoid arthritis becomes the first indication
The project narrows from a broad cannabinoid thesis to a defined, measurable development question in chronic inflammatory disease.
THCA PURE™ becomes the shared platform strategy
THCA PURE™ Oral is the lead development program. THCA PURE™ Inhale remains a future route-specific program.
From observation to hypothesis. From hypothesis to validation. From validation to responsible application.
A clear mission. A long-term scientific vision.
The objective is not to assume that THCA is already a medicine. It is to create the evidence required to determine whether it can become one.
Advance purified THCA through evidence-led pharmaceutical development.
To build a disciplined development program that connects published preclinical rationale with product characterization, nonclinical assessment, regulatory engagement and—when justified—controlled human research.
Build a specialized biotechnology company recognized for THCA science.
To establish THCA Therapeutics as a credible, internationally relevant developer of rigorously characterized THCA candidates, beginning with rheumatoid arthritis and expanding only when data support the next step.
Founder-led today. Built to become a multidisciplinary organization.
THCA Therapeutics is currently led by its founder while the scientific, clinical, regulatory, CMC and governance network required for the next stage is being assembled.
Farbod Parvin
Farbod Parvin founded THCA Therapeutics to translate a long-standing interest in THCA into a structured pharmaceutical-development program. He currently leads the project’s vision, strategy, external engagement and platform development.
Farbod is the Chief Executive Officer and leads the company’s development together with qualified scientific, clinical, regulatory, manufacturing and governance specialists.
Vision & company strategy
Defining the long-term direction, indication focus and evidence-led development model.
Platform & program leadership
Coordinating the THCA PURE™ strategy and maintaining focus on the lead oral program.
Partnerships & fundraising
Building relationships with investors, laboratories, CROs, CDMOs, advisors and academic institutions.
Strategic communication
Presenting the opportunity accurately while separating established evidence from hypotheses and future plans.
“My role is to build the structure, assemble the right expertise and ensure that the scientific question is tested responsibly.”
Transparent about what is defined—and what remains to be proven.
Credibility begins with an accurate description of progress. THCA Therapeutics is in candidate and preclinical preparation, not clinical development.
Strategic work completed
- Founder-led company thesis
- Rheumatoid arthritis selected as lead indication
- Published-evidence dossier assembled
- THCA PURE™ platform and two-program strategy defined
- Preliminary IP and prior-art assessment documented
Preparation and network building
- Business administration and operating infrastructure
- Scientific, CMC and regulatory network development
- Materials and analytical-development planning
- Prototype-feasibility preparation
- CRO, CDMO and laboratory discussions
Data and authorizations still required
- Validated product candidate and shelf life
- Company-generated animal or human data
- GMP clinical batch
- Clinical-trial authorization
- Filed patent or established freedom to operate
A focused internal core supported by specialist partners.
THCA Therapeutics intends to retain program direction, candidate definition, evidence standards, data interpretation and strategic decision-making while engaging qualified external specialists for execution.
Strategy · candidate definition · quality oversight · evidence interpretation · partnerships · capital allocation
Scientific advisors
Rheumatology, immunology, cannabinoid science, pharmacology and translational-development expertise.
Network under developmentAnalytical laboratories
Identity, assay, degradation, quality, release and bioanalytical method support.
Partner selection plannedCDMO partners
Formulation development, process feasibility, phase-appropriate manufacturing and packaging.
Feasibility engagement plannedNonclinical CROs
Safety, exposure, pharmacology and translational study execution under appropriate quality standards.
Future work packageClinical partners
Clinical pharmacology, academic rheumatology, GCP operations, biomarker strategy and patient studies.
Subject to readinessRegulatory & IP counsel
Scientific advice, submission strategy, quality documentation, patent assessment and freedom-to-operate review.
Specialist support requiredThe principles behind every development decision.
The culture of THCA Therapeutics is intended to be rigorous enough for pharmaceutical development, transparent enough to earn trust and agile enough to make difficult decisions early.
Science
Ask precise questions and generate evidence capable of answering them.
Integrity
Distinguish published evidence, company data, hypotheses and plans.
Quality
Build analytical, manufacturing and documentation standards early.
Focus
Prioritize one lead program and avoid expansion before proof.
Collaboration
Combine founder leadership with qualified multidisciplinary expertise.
Patient impact
Pursue development only where a meaningful contribution is plausible.
The next chapter is built through evidence, expertise and execution.
The immediate objective is to convert a documented scientific and product thesis into measurable candidate-development data, a regulator-informed plan and an organization capable of responsible human translation.
THCA Therapeutics is a Munich-based biotechnology business operated by Farbod Parvin as a sole proprietor. THCA PURE™ Oral and THCA PURE™ Inhale are investigational development concepts and are not approved for medical or commercial use. No product-specific human efficacy, safety, stability, bioavailability, patent protection or freedom-to-operate conclusion is claimed.
